DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
20.78
+1.98 (10.53%)
At close: Jan 16, 2026, 4:00 PM EST
20.99
+0.21 (1.01%)
After-hours: Jan 16, 2026, 7:41 PM EST
DBV Technologies Employees
As of December 31, 2024, DBV Technologies had 110 total employees, including 109 full-time and 1 part-time employees. The number of employees increased by 5 or 4.76% compared to the previous year.
Employees
110
Change (1Y)
5
Growth (1Y)
4.76%
Revenue / Employee
$50,018
Profits / Employee
-$1,137,573
Market Cap
1.26B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110 | 5 | 4.76% |
| Dec 31, 2023 | 105 | 19 | 22.09% |
| Dec 31, 2022 | 86 | -6 | -6.52% |
| Dec 31, 2021 | 92 | -50 | -35.21% |
| Dec 31, 2020 | 142 | -169 | -54.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DBVT News
- 2 days ago - DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing - GlobeNewsWire
- 6 days ago - Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 13 days ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 4 weeks ago - Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing - Benzinga
- 4 weeks ago - DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript - Seeking Alpha
- 2 months ago - DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - GlobeNewsWire
- 2 months ago - DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 2 months ago - DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - GlobeNewsWire